Disease · Orphanet_79211
Combined hyperlipidemia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Combined hyperlipidemia. Diseases, record Orphanet_79211. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/Orphanet_79211
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Combined hyperlipidemia
- Open Targets ID
- Orphanet_79211
- Other names
Combined Hyperlipidemia, Familial, Combined Hyperlipidemias, Familial, Combined hyperlipoproteinemia, FCHL - Familial combined hyperlipidaemia, FCHL - Familial combined hyperlipidemia, Familial Combined Hyperlipidemias, Familial combined hyperlipidaemia, Familial hyperlipoproteinaemia type IIb, Familial hyperlipoproteinemia type IIb, Familial multiple lipoprotein-type hyperlipidaemia, Familial multiple lipoprotein-type hyperlipidemia, Fredrickson type IIb hyperlipoproteinaemia, Fredrickson type IIb hyperlipoproteinemia, Hyperapobetalipoproteinaemia, Hyperapobetalipoproteinemia, Hyperlipidemia, Familial Combined, Hyperlipidemia, Multiple Lipoprotein Type, Hyperlipidemias, Familial Combined, Hyperlipidemias, Multiple Lipoprotein-Type, Lipoprotein-Type Hyperlipidemia, Multiple, Lipoprotein-Type Hyperlipidemias, Multiple, Mixed hyperlipidaemia, Mixed hyperlipidemia, Mixed hyperlipidemia (disorder), Mixed hyperlipoproteinemia, Multiple Lipoprotein-Type Hyperlipidemia, Multiple Lipoprotein-Type Hyperlipidemias, Multiple-type hyperlipidaemia, Multiple-type hyperlipidemia, familial combined hyperlipidemia, familial combined hyperlipidemia (disorder), familial combined hyperlipidemia (disorder) [Ambiguous], familial multiple lipoprotein-type hyperlipidemia (disorder), hyperbetalipoproteinemia with prebetalipoproteinemia, type IIb hyperlipoproteinemia
- Highest stage of its drugs
- Phase 3, for 19 of its 26 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs26
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| NIACIN | CHEMBL573 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 6 | Drugs and targets |
| SIMVASTATIN | CHEMBL1064 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| FENOFIBRATE | CHEMBL672 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| FENOFIBRIC ACID | CHEMBL981 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| LAROPIPRANT | CHEMBL426559 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ATORVASTATIN | CHEMBL1487 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| EVOLOCUMAB | CHEMBL2364655 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| EZETIMIBE | CHEMBL1138 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ONGERICIMAB | CHEMBL4594566 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PRAVASTATIN | CHEMBL1144 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 26
See all 26 drugsTargets11
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 6 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| PCSK9 | Proprotein convertase subtilisin/kexin type 9 | 3 | Subtilisin/kexin type 9 inhibitor | Phase 3 | https://conductscience.org/library/genes/255738 | Drugs and targets |
| PPARA | Peroxisome proliferator-activated receptor | 3 | Peroxisome proliferator-activated receptor agonist; Peroxisome proliferator-activated receptor alpha agonist | Phase 3 | https://conductscience.org/library/genes/5465 | Drugs and targets |
| CETP | Cholesteryl ester transfer protein | 2 | Cholesteryl ester transfer protein inhibitor | Phase 3 | https://conductscience.org/library/genes/1071 | Drugs and targets |
| FDFT1 | Squalene synthase | 1 | Squalene synthetase inhibitor | Phase 2 | https://conductscience.org/library/genes/2222 | Drugs and targets |
| HCAR2 | Hydroxycarboxylic acid receptor 2 | 1 | Hydroxycarboxylic acid receptor 2 agonist | Phase 2 | https://conductscience.org/library/genes/338442 | Drugs and targets |
| NPC1L1 | NPC1-like intracellular cholesterol transporter 1 | 1 | Niemann-Pick C1-like protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/29881 | Drugs and targets |
| NR1H4 | Bile acid receptor | 1 | Bile acid receptor FXR agonist | Early phase 1 | https://conductscience.org/library/genes/9971 | Drugs and targets |
| PPARD | Peroxisome proliferator-activated receptor | 1 | Peroxisome proliferator-activated receptor agonist | Phase 3 | https://conductscience.org/library/genes/5467 | Drugs and targets |
| PPARG | Peroxisome proliferator-activated receptor | 1 | Peroxisome proliferator-activated receptor agonist | Phase 3 | https://conductscience.org/library/genes/5468 | Drugs and targets |
1 to 10 of 11
See all 11 targetsTrials39
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00479882 | MK-0524B Lipid Study (MK-0524B-063) | Phase 3 | 2,414 | 2016-04-01 | Primary Hypercholesterolemia, Mixed Dyslipidemia | LAROPIPRANT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00289900 | Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024) | Phase 3 | 2,340 | 2016-01-26 | Mixed Hyperlipidemia | LAROPIPRANT, NIACIN, SIMVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT00300430 | Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. | Phase 3 | 1,911 | 2009-07-23 | Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia | ATORVASTATIN CALCIUM, FENOFIBRIC ACID, ROSUVASTATIN CALCIUM, SIMVASTATIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00300482 | Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood | Phase 3 | 1,445 | 2009-03-25 | Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia | FENOFIBRIC ACID, ROSUVASTATIN CALCIUM | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00479388 | Study of Extended Release Niacin/Laropiprant on Lipids (0524A-067) | Phase 3 | 1,216 | 2009-07-31 | Primary Hypercholesterolemia, Mixed Dyslipidemia | LAROPIPRANT, NIACIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01274559 | Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) | Phase 3 | 1,173 | 2014-03-14 | Primary Hypercholesterolemia, Mixed Dyslipidemia | NIACIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01335997 | Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) | Phase 3 | 1,139 | 2016-06-21 | Primary Hypercholesterolemia, Mixed Dyslipidemia | LAROPIPRANT, NIACIN, SIMVASTATIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00300456 | Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood | Phase 3 | 657 | 2009-03-25 | Dyslipidemia, Coronary Heart Disease, Mixed Dyslipidemia | FENOFIBRIC ACID, SIMVASTATIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00536510 | Effect of MK0524A on Cholesterol Levels (0524A-048) | Phase 3 | 646 | 2009-05-13 | Hypercholesterolemia, Hyperlipidemia | LAROPIPRANT, NIACIN | Its record names the disease | ClinicalTrials.gov |
| NCT00941603 | Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675) | Phase 2 | 619 | 2016-04-12 | Primary Hypercholesterolemia, Mixed Hyperlipidemia | SCH-900271 | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 39
See all 39 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Extended-release Niacin/Laropiprant vs Placebo: serious adverse events | 23 of 572 | 16 of 572 | 1,144 | NCT01274559 | Trial comparisons |
| MK0524A 2 g vs Placebo: serious adverse events | 3 of 321 | 2 of 323 | 644 | NCT00536510 | Trial comparisons |
| Evolocumab vs Placebo: deaths from any cause | 1 of 280 | 0 of 141 | 421 | NCT02739984 | Trial comparisons |
| Evolocumab vs Placebo: serious adverse events | 14 of 280 | 2 of 141 | 421 | NCT02739984 | Trial comparisons |
| Evolocumab AMD vs Evolocumab AI/Pen: serious adverse events | 0 of 82 | 1 of 82 | 164 | NCT01879319 | Trial comparisons |
| Evolocumab PFS vs Evolocumab AI/Pen: serious adverse events | 3 of 75 | 2 of 74 | 149 | NCT01849497 | Trial comparisons |
Papers from its trials40
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/Orphanet_79211
GET https://conductscience.org/api/diseases/v1/Orphanet_79211/drugs?page=2